Arcutis Biotherapeutics Inc (NASDAQ: ARQT) kicked off on Monday, up 5.93% from the previous trading day, before settling in for the closing price of $15.01. Over the past 52 weeks, ARQT has traded in a range of $7.86-$17.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -0.98% over the last five years. While this was happening, its average annual earnings per share was recorded 52.80%. With a float of $104.81 million, this company’s outstanding shares have now reached $119.14 million.
The firm has a total of 342 workers. Let’s measure their productivity. In terms of profitability, gross margin is 88.39%, operating margin of -57.0%, and the pretax margin is -60.67%.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arcutis Biotherapeutics Inc is 12.07%, while institutional ownership is 98.78%. The most recent insider transaction that took place on Jul 10 ’25, was worth 346,046. In this transaction an insider of this company sold 23,000 shares at a rate of $15.05, taking the stock ownership to the 115,468 shares. Before that another transaction happened on Jul 14 ’25, when Company’s insider sold 5,750 for $15.07, making the entire transaction worth $86,654. This insider now owns 115,468 shares in total.
Arcutis Biotherapeutics Inc (ARQT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 52.80% per share during the next fiscal year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Take a look at Arcutis Biotherapeutics Inc’s (ARQT) current performance indicators. Last quarter, stock had a quick ratio of 3.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.04, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach 0.15 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Analysing the last 5-days average volume posted by the [Arcutis Biotherapeutics Inc, ARQT], we can find that recorded value of 1.85 million was lower than the volume posted last year of 2.23 million. As of the previous 9 days, the stock’s Stochastic %D was 93.41%.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 69.17%, which indicates a significant decrease from 98.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.67 in the past 14 days, which was lower than the 0.93 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.00, while its 200-day Moving Average is $12.96. Now, the first resistance to watch is $16.25. This is followed by the second major resistance level at $16.59. The third major resistance level sits at $17.26. If the price goes on to break the first support level at $15.24, it is likely to go to the next support level at $14.57. Should the price break the second support level, the third support level stands at $14.23.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
The company with the Market Capitalisation of 1.90 billion has total of 119,202K Shares Outstanding. Its annual sales at the moment are 196,540 K in contrast with the sum of -140,040 K annual income. Company’s last quarter sales were recorded 65,850 K and last quarter income was -25,060 K.
